AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Supernus Pharmaceuticals, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SFKFF1
40.70▼ 1.37 (-3.26%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
42.07
Day's Range
39.96 – 41.95
52-Week Range
37.54 – 59.74
Volume
1.2M
Avg Volume
803.0K
Share Statistics
Shares Outstanding
Employees
778
Exchange
XNAS
Listed
2012-05-01
Share count as of July 28, 2026

Supernus Pharmaceuticals, Inc. (SUPN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Supernus Pharmaceuticals, Inc. (SUPN)
What is Supernus Pharmaceuticals, Inc.'s Market Cap?
Supernus Pharmaceuticals, Inc.'s Market Cap is $2.4B, based on as-reported figures from SEC (XBRL) filings.
What is Supernus Pharmaceuticals, Inc.'s Price / Sales?
Supernus Pharmaceuticals, Inc.'s Price / Sales is 2.8×, based on as-reported figures from SEC (XBRL) filings.
What is Supernus Pharmaceuticals, Inc.'s Revenue (TTM)?
Supernus Pharmaceuticals, Inc.'s Revenue (TTM) is $830.4M, based on as-reported figures from SEC (XBRL) filings.
What is Supernus Pharmaceuticals, Inc.'s Net Income (TTM)?
Supernus Pharmaceuticals, Inc.'s Net Income (TTM) is -$109.9M, based on as-reported figures from SEC (XBRL) filings.
What is Supernus Pharmaceuticals, Inc.'s EBITDA?
Supernus Pharmaceuticals, Inc.'s EBITDA is -$28.8M, based on as-reported figures from SEC (XBRL) filings.
What is Supernus Pharmaceuticals, Inc.'s Diluted EPS (TTM)?
Supernus Pharmaceuticals, Inc.'s Diluted EPS (TTM) is -1.89, based on as-reported figures from SEC (XBRL) filings.
What is Supernus Pharmaceuticals, Inc.'s EBITDA Margin?
Supernus Pharmaceuticals, Inc.'s EBITDA Margin is -3.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SUPNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
Total revenues
YoY growth+32.4%+38.6%+21.5%+9.3%
Costs and expenses
Cost of revenues
Research and development
Selling, general and administrative
Amortization of intangible assets
Intangible asset impairment charges———
Contingent consideration loss
Total costs and expenses
% of revenue126.5%104.0%101.9%131.4%
Operating earnings (loss)
% of revenue-26.5%-4.0%-1.9%-31.4%
Other income (expense)
Interest and other income, net
Interest expense———
Total other income, net
Earnings (loss) before income taxes
Income tax expense (benefit)
Net earnings (loss)
% of revenue-26.6%-1.1%-1.9%-23.5%
Earnings (loss) per share
Basic (in dollars per share)
Diluted (in dollars per share)